Avner Schlessinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9099851/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PredictProtein—an open resource for online prediction of protein structural and functional features. Nucleic Acids Research, 2014, 42, W337-W343.	14.5	589
2	Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nature Chemical Biology, 2011, 7, 769-778.	8.0	285
3	Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder. Cell, 2016, 167, 1481-1494.e18.	28.9	265
4	Crystal structure of a eukaryotic phosphate transporter. Nature, 2013, 496, 533-536.	27.8	202
5	Function of human Rh based on structure of RhCG at 2.1Ââ"«. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9638-9643.	7.1	178
6	Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5480-5485.	7.1	173
7	Improved Disorder Prediction by Combination of Orthogonal Approaches. PLoS ONE, 2009, 4, e4433.	2.5	170
8	Protein flexibility and rigidity predicted from sequence. Proteins: Structure, Function and Bioinformatics, 2005, 61, 115-126.	2.6	161
9	SLC transporters: structure, function, and drug discovery. MedChemComm, 2016, 7, 1069-1081.	3.4	152
10	Evolution of modular intraflagellar transport from a coatomer-like progenitor. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6943-6948.	7.1	144
11	PROFbval: predict flexible and rigid residues in proteins. Bioinformatics, 2006, 22, 891-893.	4.1	135
12	PredictProtein - Predicting Protein Structure and Function for 29 Years. Nucleic Acids Research, 2021, 49, W535-W540.	14.5	135
13	Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15810-15815.	7.1	120
14	Artificial intelligence and machine learningâ€aided drug discovery in central nervous system diseases: Stateâ€ofâ€ŧheâ€arts and future directions. Medicinal Research Reviews, 2021, 41, 1427-1473.	10.5	120
15	Natively unstructured regions in proteins identified from contact predictions. Bioinformatics, 2007, 23, 2376-2384.	4.1	118
16	Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase. Cell Chemical Biology, 2016, 23, 837-848.	5.2	100
17	Comparison of human solute carriers. Protein Science, 2010, 19, 412-428.	7.6	99
18	Structural basis for alternating access of a eukaryotic calcium/proton exchanger. Nature, 2013, 499, 107-110.	27.8	87

#	Article	IF	CITATIONS
19	Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters. Current Topics in Medicinal Chemistry, 2013, 13, 843-856.	2.1	85
20	Natively Unstructured Loops Differ from Other Loops. PLoS Computational Biology, 2007, 3, e140.	3.2	84
21	Epitome: database of structure-inferred antigenic epitopes. Nucleic Acids Research, 2006, 34, D777-D780.	14.5	78
22	Large-Scale Analysis of Thermostable, Mammalian Proteins Provides Insights into the Intrinsically Disordered Proteome. Journal of Proteome Research, 2009, 8, 211-226.	3.7	76
23	Automated Identification of Complementarity Determining Regions (CDRs) Reveals Peculiar Characteristics of CDRs and B Cell Epitopes. Journal of Immunology, 2008, 181, 6230-6235.	0.8	73
24	Loss-of-function variants of SETD5 cause intellectual disability and the core phenotype of microdeletion 3p25.3 syndrome. European Journal of Human Genetics, 2015, 23, 753-760.	2.8	73
25	Genetic Polymorphisms in Organic Cation Transporter 1 (OCT1) in Chinese and Japanese Populations Exhibit Altered Function. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 42-50.	2.5	72
26	Redefining the Protein Kinase Conformational Space with Machine Learning. Cell Chemical Biology, 2018, 25, 916-924.e2.	5.2	65
27	Integrative Structure Modeling of Macromolecular Assemblies from Proteomics Data. Molecular and Cellular Proteomics, 2010, 9, 1689-1702.	3.8	64
28	Coordinating the impact of structural genomics on the human α-helical transmembrane proteome. Nature Structural and Molecular Biology, 2013, 20, 135-138.	8.2	64
29	Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening. PLoS Computational Biology, 2015, 11, e1004477.	3.2	62
30	Mutations in the Na+/Citrate Cotransporter NaCT (SLC13A5) in Pediatric Patients with Epilepsy and Developmental Delay. Molecular Medicine, 2016, 22, 310-321.	4.4	59
31	A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nature Chemical Biology, 2018, 14, 291-298.	8.0	56
32	LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5000-5006.	2.2	54
33	Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). Journal of Medicinal Chemistry, 2018, 61, 7358-7373.	6.4	54
34	LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2616-2621.	2.2	53
35	High Selectivity of the γ-Aminobutyric Acid Transporter 2 (GAT-2, SLC6A13) Revealed by Structure-based Approach. Journal of Biological Chemistry, 2012, 287, 37745-37756.	3.4	49
36	Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening. ACS Chemical Biology, 2016, 11, 1908-1916.	3.4	49

#	Article	IF	CITATIONS
37	Molecular Modeling of Drug–Transporter Interactions—An International Transporter Consortium Perspective. Clinical Pharmacology and Therapeutics, 2018, 104, 818-835.	4.7	43
38	Crowdsourced mapping of unexplored target space of kinase inhibitors. Nature Communications, 2021, 12, 3307.	12.8	41
39	Advances and Challenges in Rational Drug Design for SLCs. Trends in Pharmacological Sciences, 2019, 40, 790-800.	8.7	40
40	An IRAK1–PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nature Cell Biology, 2019, 21, 203-213.	10.3	38
41	DFGmodel: Predicting Protein Kinase Structures in Inactive States for Structure-Based Discovery of Type-II Inhibitors. ACS Chemical Biology, 2015, 10, 269-278.	3.4	37
42	Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity. European Journal of Medicinal Chemistry, 2018, 157, 1005-1016.	5.5	36
43	Rational design of ASCT2 inhibitors using an integrated experimental-computational approach. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	35
44	An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters. Frontiers in Pharmacology, 2021, 12, 722889.	3.5	31
45	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discovery, 2021, 11, 1716-1735.	9.4	30
46	Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 398-402.	2.2	29
47	Effects of Mutations and Ligands on the Thermostability of the l-Arginine/Agmatine Antiporter AdiC and Deduced Insights into Ligand-Binding of Human I-Type Amino Acid Transporters. International Journal of Molecular Sciences, 2018, 19, 918.	4.1	29
48	Association of Autism Spectrum Disorder With Prenatal Exposure to Medication Affecting Neurotransmitter Systems. JAMA Psychiatry, 2018, 75, 1217.	11.0	28
49	KinaMetrix: a web resource to investigate kinase conformations and inhibitor space. Nucleic Acids Research, 2019, 47, D361-D366.	14.5	28
50	Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity. Nature Communications, 2020, 11, 4809.	12.8	28
51	Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7819-7824.	7.1	27
52	Structure-Based Identification of Inhibitors for the SLC13 Family of Na+/Dicarboxylate Cotransporters. Biochemistry, 2015, 54, 4900-4908.	2.5	26
53	Determinants of Substrate and Cation Transport in the Human Na+/Dicarboxylate Cotransporter NaDC3. Journal of Biological Chemistry, 2014, 289, 16998-17008.	3.4	24
54	Interaction of Bacillus subtilis Polynucleotide Phosphorylase and RNase Y. Journal of Biological Chemistry, 2016, 291, 6655-6663.	3.4	24

#	Article	IF	CITATIONS
55	Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds. Journal of General Physiology, 2019, 151, 357-368.	1.9	24
56	High-Resolution Structure and Inhibition of the Schizophrenia-Linked Pseudokinase ULK4. Journal of the American Chemical Society, 2020, 142, 33-37.	13.7	24
57	Identification of newborns at risk for autism using electronic medical records and machine learning. European Psychiatry, 2020, 63, e22.	0.2	24
58	<i>SLC13A3</i> variants cause acute reversible leukoencephalopathy and αâ€ketoglutarate accumulation. Annals of Neurology, 2019, 85, 385-395.	5.3	22
59	Homology Modeling Informs Ligand Discovery for the Glutamine Transporter ASCT2. Frontiers in Chemistry, 2018, 6, 279.	3.6	21
60	Human neurons from Christianson syndrome iPSCs reveal mutation-specific responses to rescue strategies. Science Translational Medicine, 2021, 13, .	12.4	21
61	Identification of discriminative gene-level and protein-level features associated with pathogenic gain-of-function and loss-of-function variants. American Journal of Human Genetics, 2021, 108, 2301-2318.	6.2	21
62	Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1. Molecular Pharmaceutics, 2017, 14, 4685-4693.	4.6	20
63	Identification of a G-Protein-Independent Activator of GIRK Channels. Cell Reports, 2020, 31, 107770.	6.4	20
64	GEN3VA: aggregation and analysis of gene expression signatures from related studies. BMC Bioinformatics, 2016, 17, 461.	2.6	17
65	Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer. Biochemistry, 2017, 56, 3475-3483.	2.5	15
66	SLC16 Family: From Atomic Structure to Human Disease. Trends in Biochemical Sciences, 2021, 46, 28-40.	7.5	15
67	Encounter and React: Computer-Guided Design of Covalent Inhibitors. Cell Chemical Biology, 2019, 26, 6-8.	5.2	14
68	Multi-targeting Drug Community Challenge. Cell Chemical Biology, 2017, 24, 1434-1435.	5.2	13
69	l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2254-2258.	2.2	13
70	Functional and structural analysis of rare SLC2A2 variants associated with Fanconiâ€Bickel syndrome and metabolic traits. Human Mutation, 2019, 40, 983-995.	2.5	13
71	Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. ELife, 2021, 10, .	6.0	12
72	Environmental Pressure May Change the Composition Protein Disorder in Prokaryotes. PLoS ONE, 2015, 10, e0133990.	2.5	11

#	Article	IF	CITATIONS
73	Mapping Functionally Important Residues in the Na ⁺ /Dicarboxylate Cotransporter, NaDC1. Biochemistry, 2017, 56, 4432-4441.	2.5	10
74	Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network. PLoS Computational Biology, 2019, 15, e1006878.	3.2	10
75	Maternal health around pregnancy and autism risk: a diagnosis-wide, population-based study. Psychological Medicine, 2022, 52, 4076-4084.	4.5	10
76	Generation of G protein-coupled receptor antibodies differentially sensitive to conformational states. PLoS ONE, 2017, 12, e0187306.	2.5	10
77	Exploring the conformational diversity of proteins. ELife, 2022, 11, .	6.0	10
78	Systems Pharmacology: An Overview. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 53-80.	0.6	7
79	Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge. PLoS Computational Biology, 2021, 17, e1009302.	3.2	7
80	Computing Substrate Selectivity in a Peptide Transporter. Cell Chemical Biology, 2016, 23, 211-213.	5.2	6
81	Type II Binders Targeting the "GLR-Out―Conformation of the Pseudokinase STRADα. Biochemistry, 2021, 60, 289-302.	2.5	6
82	The Effects of Prodrug Size and a Carbonyl Linker on <scp>l</scp> â€Type Amino Acid Transporter 1â€Targeted Cellular and Brain Uptake. ChemMedChem, 2021, 16, 869-880.	3.2	5
83	Protein structure–based gene expression signatures. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	5
84	Interaction of the neutral amino acid transporter ASCT2 with basic amino acids. Biochemical Journal, 2020, 477, 1443-1457.	3.7	4
85	Alanine serine cysteine transporter (ASCT) substrate binding site properties probed with hydroxyhomoserine esters. Journal of Physical Organic Chemistry, 2022, 35, .	1.9	4
86	Co-expression and co-localization of hub proteins and their partners are encoded in protein sequence. Molecular BioSystems, 2014, 10, 787.	2.9	1
87	Inside Back Cover Image, Volume 41, Issue 3. Medicinal Research Reviews, 2021, 41, iii.	10.5	0